-
Dangote, Nigeria's oil tycoon rewriting Africa's story
-
Two charged with UK security offences over airbase plot: police
-
Carrick to remain Man Utd boss for Chelsea clash: reports
-
Maresca defends Donnarumma, Guehi after Man City defeat
-
Greenhouse gas levels hit new record highs in 2025: UN
-
Nordic leaders call Putin as local truce begins in Ukraine
-
Rybakina looking to clinch year-end number one in Tokyo
-
Osaka unveils crane outfit in Tokyo before win over Paolini
-
Tech firms track Wall St rally on mixed day for stock markets
-
Ronaldo in line for Portugal return after fallout with coach
-
Kane says Ballon d'Or win 'feels like a dream' as tributes pour in
-
Norway media take legal action to block Meta from using content
-
HSBC profit jumps on higher rates, lower costs
-
Bayern praise 'humble' Kane after Ballon d'Or win
-
Rams rediscover offensive balance in 35-21 victory over Raiders
-
Colts retain Daniel Jones as starter despite continued offensive struggles
-
Mercedes-Benz cuts 2026 profit outlook on tough China market
-
Madushanka wrecks Pakistan as Sri Lanka press for final slot
-
Reparations calls follow Charles on tough Caribbean trip
-
Destructive Abhishek 113 leads India to series win over New Zealand
-
Jammu and Kashmir ministers resign before planned council expansion
-
Norway, Finland leaders hold 'frank and substantive' talk with Putin
-
Germany, EU, stable investment stops despite upheaval: Merz
-
Wall Street faces earnings and Fed tests after turbulent technology-led week
-
China brands drop Mbappe for 'offending national sentiments'
-
Ukraine, Russia say US-brokered truce holding in ravaged city
-
India orders evacuations as Cyclone Arnab looms
-
Police form SIT after vehicles in Rahul Gandhi convoy collide on expressway
-
Dutch broadcaster pulls out of Eurovision over Israel 'sensitivities'
-
Delhi grants minimum monthly pay and DA to about 4,000 MCD health workers
-
Critical coal inventories affect nearly half of India’s domestic power plants
-
Ather Energy shares climb 14% after quarterly profit and expansion plan
-
FCNR(B) deposit drive puts sharper margin pressure on private banks
-
Gold ETF flows turn negative after 13 weeks as bullion loses 4%
-
Noel Tata requests records of September 17 Tata Sons board meeting
-
Pakistan's last antique restorers give old treasures new life
-
Reparations calls to dog King Charles's tough Caribbean trip
-
India braces for Cyclone Arnab with evacuations
-
Global rates and foreign outflows remain key risks for Indian markets
-
Steel Strips Wheels gains 36% in two sessions on growth outlook
-
Neha Nagar says ₹3 crore can fund retirement with disciplined planning
-
Cavs edge T'Wolves in overtime despite superb Edwards
-
Vikas Satija says steady SIP flows shielded Indian equities from deeper losses
-
Prescott fires Cowboys to 38-21 win over plummeting Eagles
-
Brewers rout Rays to reach brink of World Series sweep
-
Kuwait padel chief hails national showing at Premier Padel Major
-
Mbappe dropped by Chinese brands for 'offending national sentiments'
-
Britain prepares constrained budget as debt and defence pressures mount
-
Kuwait exhibition presents Ukraine’s Islamic heritage and cultural ties
-
Valkyries beat Dream to reach brink of WNBA title
CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026
SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2026, after the stock market closes on Thursday, May 14, 2026. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1760203&tp_key=9a8cb9d283.
The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, May 21, 2026, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13760149.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
O.Norris--AMWN